Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | Prospective Grant of Exclusive License: Devices for Treating Dysphagia and Dysphonia | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 6, 2011 will be considered. | ||
| View | Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments | The public hearing will be held November 2 and 3, 2010, from 8:30 a.m. to 4:30 p.m. Individuals who wish to present at the public hearing must register on or before October 11, 2010. Section III of this document provides attendance and registration information. Electronic or written comments will be accepted after the public hearing until December 31, 2010. | ||
| View | Prospective Grant of Exclusive License: Prevention, Prophylaxis, Cure, Amelioration, and/or Treatment of Infection and/or the Effects Thereof of Chikungunya Infections in Humans | Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before October 25, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Immunotoxins/Targeted Toxins for the Treatment of Human Cancers | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 14, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Development of AAV5 Based Therapeutics To Treat Human Diseases | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 14, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Use of Pentosan Polysulfate To Treat Certain Conditions of the Prostate | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 1, 2010 will be considered. | ||
| View | Prospective Grant of a Co-Exclusive License: Natural Plant Extracts From Incense Cedar as Pest Control Agents and Methods for Their Use | December 8, 2000. | ||
| View | Prospective Grant of Exclusive License: Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates as Biotherapeutics for the Treatment of HIV and HCV Infections | Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before September 9, 2010 will be considered. | ||
| View | Comprehensive List of Guidance Documents at the Food and Drug Administration | We welcome general comments on this list and on agency guidance documents at any time. | ||
| View | Prospective Grant of Exclusive License: Use of Leptin and Leptin Analogs for the Treatment of Lipodystrophy | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 27, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Human Therapeutics for the Treatment of Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 3, 2010 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | 2008-09-05 (HHS Reference No. E-238-2008/2-PCT-01). | ||
| View | Cancer Therapy Evaluation Program Intellectual Property Option to Collaborator | Comments must be received by NIH on or before May 6, 2010. | ||
| View | Prospective Grant of Exclusive License: Development of PANVAC and Tumor Associated Antigens as Cancer Vaccines | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 3, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Treatment of Glaucoma by Administration of Adenosine A3 Antagonists | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 29, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Purified Inactivated Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3′-UTR of Dengue Types 1,2,3, and 4 | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 10, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Monoclonal Antibodies Against Smallpox/Orthopoxviruses | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 19, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Development of V-ATPase Inhibitor Compounds for the Treatment of Human Cancers and Osteoclastic Bone Diseases Excluding Rheumatoid Arthritis and Other Osteo-Specific Auto-Immune Diseases | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 12, 2010 will be considered. | ||
| View | Prospective Granting of an Exclusive License | 12/27/2002. | ||
| View | Prospective Grant of Exclusive License: Development of a Companion Diagnostic Kit To Detect Asparagine Synthetase Expression Levels as a Method To Screen for the Drug Efficacy in Treatments for Pancreatic Cancer, Ovarian Cancer, and Multiple Myeloma | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before January 4, 2010 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: Development of Anti-Angiogenesis Cancer Therapeutics Targeting Adrenomedullin or Proadrenomedullin N-Terminal 20 Peptide (PAMP) | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 30, 2009 will be considered. | ||
| View | Office of the Commissioner Reorganization; Statement of Organizations, Functions, and Delegations of Authority | |||
| View | The National Biodefense Science Board (NBSB), a Federal Advisory Committee to the Secretary; Request for Public Comment | The public is asked to submit comments by October 30, 2009, to the NBSB e-mail box (NBSB@hhs.gov) in order to be considered by the Working Group in preparing the final document. | ||
| View | Government-Owned Inventions; Availability for Licensing |